"We believe these pathways are very important in the airway inflammation that occurs in asthma patients," said Kenyon, who directs the predoctoral research training program of the UC Davis Clinical and Translational Science Center (CTSC). "Presently, we have medications that block related pathways in asthma, but what we will look at is very new. We are excited to see if soluble epoxide hydrolase inhibitors, with or without these other medications, can improve the quality of life for patients with persistent asthma."
Yang said the project "will use the new omics technology -- metabolomics --to assist the diagnosis and monitor asthma therapy."
"The metabolomics is already used to predict the drug toxicity in the earlier stage and it is also expected to play an important role in the personal medicine," Yang said. "We anticipate that this technology will eventually help us to find new ways to diagnose asthma as well as monitor its treatment."
Through its national grants program, the American Asthma Foundation (AAF) sponsors highly innovative, cutting-edge research, recruiting investigators "to think outside the box" to bring new perspectives to diseases of the lung, according to its Web site.
Hammock lab researchers have demonstrated that sEH inhibitors are strongly synergistic with current asthma drugs: cycloxygenase inhibitors and several of the blockers of leukotriene biosynthesis.
"We hope to both evaluate sEH inhibitors alone in treating asthma but also to combine them with other inflammatory drugs to improve their efficacy and reduce their side effects," Hammock said. "Both the analytical and novel chemical probes will give us a better understanding of the basic causes of asthma."
The enzyme is involved in the metabolism of arachidonic acid, a key
signaling molecule implicated in diabetes, hypertension and
inf
'/>"/>
| Contact: Kathy Keatley Garvey kegarvey@ucdavis.edu 530-754-6894 University of California - Davis Source:Eurekalert |